Generic Advair: Finally Approved, A Long Time Coming
Executive Summary
Mylan's generic version of GlaxoSmithKline's blockbuster asthma drug was approved by the US FDA Jan. 30. Scrip's timeline tracks how the commercial value of the drug for GSK has greatly declined from its peak in 2013.
You may also be interested in...
GSK's Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US
Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.
GSK's Trelegy On Track To Be First Triple Inhaled Regimen For Asthma
The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.
GSK's New US Pharmaceuticals President Martinez-Davis Brings Oncology Experience
US Pharmaceuticals President Jack Bailey will step down, to be succeeded by Maya Martinez-Davis, currently at Merck KGAA.